ClinicalTrials.gg
RecruitingNCT06471582FASTUpdated May 1, 2026

Timing of Energy Availability on Menstrual Cycle Function

An interventional study of Artificially Sweetened Carbohydrate Beverage and Artificially Sweetened Beverage in Menstrual Irregularity, sponsored by University of Colorado, Colorado Springs. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by University of Colorado, Colorado Springs · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Menstruation Disturbances with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Menstruation Disturbances · United States.

Planned enrollment
8th of 23
64 · median 60
Started
2024
with 1 other
No phase
9 of 29
3 open now
Registered
23rd of 29
by date

Among the 29 studies in Menstruation Disturbances with a site in United States, this one is the 8th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2024, is one of 9 with no phase, and was the 23rd registered.

Menstruation Disturbances

105 studies on the registry are indexed under Menstruation Disturbances; 23 are open to participants now.

Browse Menstruation Disturbances studies →

Open to participants now

5 of the 29 studies in Menstruation Disturbances with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Menstruation Disturbances studies recruiting now, 3 (20%) set no upper age limit and 12 (80%) stop at 75 or younger; 6 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 40 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Menstruation Disturbances with a site in United States, or all of them as a file.
02

Study summary

The primary aim of this clinical trial is to evaluate how fasted prolonged exercise may influence circulating reproductive hormones (i.e., estradiol, progesterone, luteinizing hormone) and menstrual cycle length when energy availability is maintained at or above 30 kcal/kg lean body mass/ day among women who regularly do running or cycling exercise. A secondary aim is to determine the effects of fasted prolonged exercise on serum leptin and cortisol.

Participants will be asked to do the following over a \~3 month enrollment period:

  • attend a laboratory visit at the beginning of the study to have their resting metabolic rate, aerobic fitness, and body composition tested
  • monitor their menstrual cycle length, urine hormones, perceived stress levels, and diet for \~3 months
  • complete 3, 90-minute exercise sessions on a stationary bike or treadmill either fed (consuming a carbohydrate meal 1 h prior and 0.7 g carbohydrate/ kg body mass/ h during exercise) or fasted (consuming no meal prior and no carbohydrates during exercise) during month \~3
  • saliva samples will be taken prior to and after 90-minute exercise sessions for quantification of leptin and cortisol
03

Conditions studied

  • Menstrual Irregularity

Keywords

  • functional hypothalamic amenorrhea
  • menstrual cycle
  • female athlete
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • participates in structured running or cycling exercise for at least 30 minutes on 3 or more days per week
  • accustomed to exercising for 90 minutes or more
  • has regular periods every 21-35 days
  • have not taken hormonal for at least the past 6 months
  • is not currently or trying to become pregnant or breastfeeding, and has not been pregnant or breastfeeding in the past 12 months
  • does not currently have a diagnosis of a major menstrual cycle disorder (i.e., amenorrhea, polycystic ovary syndrome [PCOS], endometriosis, ovarian cancer, ovarian insufficiency, uterine or endometrial cancer)
  • does not currently have a metabolic disease (i.e., hypothyroidism, hyperthyroidism, Cushing disease, Addison's disease, diabetes, congenital adrenal hyperplasia)
  • does not currently have a major cardiovascular or respiratory disease

Exclusion criteria

Exclusion Criteria:

  • miss more than 7 consecutive days of aerobic activity (i.e., running, cycling, cross training)
  • demonstrate clinical low energy availability as defined as energy availability \<30 kcal/kg fat free mass
  • report menstrual cycle lengths \<21 or >35 days in the first 2 months of at-home monitoring
  • do not demonstrate an anticipated rise in luteinizing hormone and progesterone in the first 2 months of at-home monitoring
  • begin taking a hormonal
  • become pregnant
  • are diagnosed with a menstrual cycle disorder (i.e., amenorrhea, polycystic ovary syndrome [PCOS], endometriosis, ovarian cancer, ovarian insufficiency, uterine, or endometrial cancer)
  • are diagnosed with a metabolic disease (i.e., hypothyroidism, hyperthyroidism, Cushing disease, Addison's disease, diabetes)
  • are diagnosed with a major cardiovascular or respiratory disease
  • are unable to follow instructions for any of the procedures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Fed with Carbohydrates

    Participants will complete 3, 90-minute stationary cycle or treadmill exercise sessions 1 h after consuming a meal containing 1 g carbohydrate/ kg body weight. During exercise, they will consume an artificially sweetened beverage containing 0.7 g carbohydrate/ kg body mass/ h as a 2:1 mixture of glucose and fructose.

    Dietary Supplement: Artificially Sweetened Carbohydrate Beverage

  • Placebo comparator
    Fasted without Carbohydrates

    Participants will complete 3, 90-minute stationary cycle or treadmill exercise sessions following an overnight fast. During exercise, they will consume an artificially sweetened beverage containing no carbohydrates.

    Dietary Supplement: Artificially Sweetened Beverage

Interventions

  • Dietary supplementArtificially Sweetened Carbohydrate Beverage

    Beverage containing 0.7 g carbohydrate/ kg body mass/ h as a 2:1 mixture of glucose and fructose and artificial sweetener

  • Dietary supplementArtificially Sweetened Beverage

    Beverage containing no carbohydrates or kilocalories and an artificial sweetener

06

What researchers measure

Primary outcomes

  1. Urinary estrone-3-glucuronide (E3G)

    ng/mL

    Time frame: 3 months

  2. Urinary pregnanediol glucuronide (PdG)

    ug/mL

    Time frame: 3 months

  3. Urinary luteinizing hormone (LH)

    MIU/mL

    Time frame: 3 months

  4. Menstrual cycle length

    days

    Time frame: 3 months

Secondary outcomes

  1. Salivary cortisol

    ng/mL

    Time frame: 3 days

  2. Salivary leptin

    ng/mL

    Time frame: 3 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Aug 2027, 36 months after the start.

Of 30 interventional studies with no phase under Menstruation Disturbances, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 36 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2024
First posted
Jun 24, 2024
StartActual
Aug 1, 2024
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06471582
Lead sponsor
University of Colorado, Colorado Springs
Responsible party
Marissa Baranauskas (Assistant Professor, University of Colorado, Colorado Springs) — Principal investigator
First posted
Jun 24, 2024
Start date
Aug 1, 2024
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
May 1, 2026

Study contacts

Marissa Baranauskas, PhD
Contact
mbaranau@uccs.edu
719-255-4475

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion